PMNOC Proceedings:

  • IMBRUVICA (ibrutinib): Pharmacyclics and Janssen v Natco Pharma

For complete details about these proceedings, click here

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.